ArticleEuropean spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society2026
Clinical outcomes of the LORDS strategy for thoracolumbar spinal metastases: a retrospective cohort study.
Article in European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo compare surgical outcomes between patients with spinal metastases who received surgical treatment concordant with the LORDS (life expectancy, operability, responsible segment, decompression, and stabilization) strategy and those who did not.
backgroundThe Neurologic, Oncologic, Mechanical, and Systemic (NOMS) framework is widely used to guide decision-making in spinal metastases. With advances in targeted therapy, immunotherapy, and surgical techniques, more patients are now candidates for anterior column resection. However, a balanced surgical strategy that is compatible with NOMS framework and surgery remains lacking.
methodsWe included 238 adult patients (≥18 years) with spinal metastases who underwent surgery between January 2018 and December 2022. Patients were categorized into the LORDS-concordant group (n = 129) and the non-concordant group (n = 109). The non-concordant group was further subdivided based on decompression extent into de-escalated (n = 37) and escalated (n = 72) subgroups. Surgical outcomes included blood loss, duration of surgery, change in Frankel grade, postoperative systemic therapy (chemotherapy, targeted therapy, immunotherapy, bone-modifying agents), radiotherapy, length of hospitalization, reoperation, complications, overall survival (OS), and local progression-free survival (LPFS).
resultsPatients who underwent surgery in accordance with the LORDS strategy exhibited a higher proportion of both radioresistant and radiosensitive individuals, while the proportion of patients with undefined radiosensitivity was lower (p = 0.030). However, this baseline difference did not reach statistical significance in subgroup analysis (p = 0.102). Furthermore, the LORDS-concordant group experienced a shorter length of hospitalization compared to the non-concordant group (p = 0.004), with subgroup analysis confirming consistent results (p < 0.001). Regarding survival outcomes, patients in the LORDS-concordant group demonstrated significantly improved OS (802.00 [95% CI: 544.00; 1332.00] days) and LPFS (530.00 [95% CI: 364.00; 980.00] days) compared to the non-concordant group (OS: 590.00 [95% CI: 283.00; 844.00] days, LPFS: 376.00 [95% CI: 234.00; 711.00] days) (p < 0.001 for OS and p = 0.008 for LPFS). Subgroup analysis further revealed longer OS and LPFS in the LORDS-concordant group compared to both the de-escalated (OS: 590.00 [95% CI: 303.00; 1179.00] days, LPFS: 280.00 [95% CI: 185.00; 759.00] days) and escalated groups (OS: 587.50 [95% CI: 275.50; 817.75] days, LPFS: 423.50 [95% CI: 240.00; 710.25] days) (p < 0.001 for OS and p = 0.008 for LPFS).
conclusionThe LORDS strategy represents an exploratory surgical framework that integrates key clinical considerations while remaining compatible with the NOMS framework. It may offer a balanced and individualized approach to surgical decision-making in spinal metastases, with the potential to optimize outcomes without increasing operative risks. Further prospective validation of the LORDS strategy and refinement of its life-expectancy assessment are warranted.
Indexed as
Identifiers
42828573What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.